Medpace (NASDAQ:MEDP) CEO Sells $30,788,695.98 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 49,018 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares in the company, valued at approximately $272,205,286.92. The trade was a 10.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $618.88 on Friday. The company has a market capitalization of $17.27 billion, a P/E ratio of 36.28, a P/E/G ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm’s 50 day simple moving average is $594.65 and its two-hundred day simple moving average is $515.99.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

A number of large investors have recently made changes to their positions in the company. Schulhoff & Co. Inc. increased its holdings in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after buying an additional 25 shares during the period. Balefire LLC boosted its holdings in shares of Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares during the last quarter. Root Financial Partners LLC boosted its holdings in shares of Medpace by 34.1% in the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock valued at $59,000 after acquiring an additional 31 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Medpace by 2.8% in the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock worth $613,000 after acquiring an additional 32 shares during the period. Finally, Handelsbanken Fonder AB raised its holdings in shares of Medpace by 0.6% during the second quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock worth $3,718,000 after purchasing an additional 40 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MEDP. TD Cowen lifted their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Mizuho upped their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $595.20.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.